Skip to main content
Home
FULL MENU Close Menu
Home
Home

Mark S. Lesney

News

Patients with CLL have significantly reduced response to COVID-19 vaccine 

Author:
Mark S. Lesney
Phd
Publish date: May 16, 2021

Less than half of CLL patients had an antibody-mediated response to the Pfizer vaccine in a study.

  • Read More

News

Combo drug improves survival in older patients with high-risk/secondary AML

Author:
Mark S. Lesney
Publish date: June 26, 2020

CPX-351 therapy was tied to long-term remission and survival in older patients with newly diagnosed high-risk or...

  • Read More

News

FDA approves twice-daily formulation of key thalassemia drug

Author:
Mark S. Lesney
Publish date: May 22, 2020

The new formulation of twice-a-day Ferriprox 1,000 mg oral tablets eliminates the midday dose.

  • Read More

News

Vaccination regimen effective in preventing pneumonia in MM patients

Author:
Mark S. Lesney
Publish date: May 21, 2020

Vaccination was effective despite the expected decrease in immunological response during target and...

  • Read More

News

Race and location appear to play a role in the incidence of CLL and DLBCL

Author:
Mark S. Lesney
Publish date: May 20, 2020

Urban non Hispanic blacks and Hispanics have an increased incidence of CLL, DLBCL, respectively vs. rural....

  • Read More

News

Secondary acute lymphoblastic leukemia more lethal than de novo

Author:
Mark S. Lesney
Publish date: May 14, 2020

Adult patients with secondary ALL had poorer overall survival than de novo ALL patients.

  • Read More

News

Protective levels of vitamin D achievable in SCD with oral supplementation

Author:
Mark S. Lesney
Publish date: May 12, 2020

Vitamin D3 prophylaxis is a safe practice in sickle cell disease, and it is important to start this prophylactic treatment when the child is an...

  • Read More

News

DLBCL patients at academic centers had significantly better survival

Author:
Mark S. Lesney
Publish date: May 11, 2020

Researchers suggested that academic centers might provide increased access to clinical trials, improved physician expertise, improved treatment...

  • Read More

News

Interleukin-27 increased cytotoxic effects of bone marrow NK cells in CLL

Author:
Mark S. Lesney
Publish date: May 6, 2020

Interleukin-27 was able to increase cytotoxic effects of bone marrow natural killer cells in chronic lymphocytic leukemia (CLL).

  • Read More

News

SARS-CoV-2 present significantly longer in stool than in respiratory, serum samples

Author:
Mark S. Lesney
Publish date: April 27, 2020

SARS-CoV-2 is present significantly longer in samples from severe COVID-19 patients than from patients with mild...

  • Read More

News

Combo therapy with melflufen promising in small r/r multiple myeloma study

Author:
Mark S. Lesney
Publish date: April 23, 2020

Melflufen plus dexamethasone showed activity in patients with relapsed/refractory multiple myeloma.

  • Read More

News

REACH2: Ruxolitinib outperformed control treatment for refractory acute GVHD

Author:
Mark S. Lesney
Publish date: April 22, 2020

Ruxolitinib was significantly more effective against acute graft-versus-host disease but produced more thrombocytopenia than did control treatment...

  • Read More

News

Five prognostic indexes come up short for planning early CLL treatment

Author:
Mark S. Lesney
Publish date: April 22, 2020

None of the indexes was able to predict with total precision the clinical evolution of Binet A chronic...

  • Read More

News

EHA and TIF explore how COVID-19 is affecting thalassemia and SCD patients

Author:
Mark S. Lesney
Publish date: April 20, 2020

Thalassemia patients appeared to fare relatively well after COVID-19 diagnosis in anecdotal series reports from...

  • Read More

News

CLAM trial regimen shown safe, effective for r/r AML

Author:
Mark S. Lesney
Publish date: April 17, 2020

High response rates and effective bridge to transplant shown.

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close